Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients

Human Psychopharmacology

Volumn 25, Issue 3, 2010, Pages 230-235

  Verma, Swapna ^a   Subramaniam, Mythily ^a   Abdin, Edimansyah ^a   Sim, Kang ^a   Su, Alex ^a   Lee, Nelson ^a   Chong, Siow Ann ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Efficacy; Long acting risperidone; Schizophrenia

Indexed keywords

CHOLESTEROL; GLUCOSE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ASIAN; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MALE; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANK SUM TEST; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; STUDENT T TEST; WEIGHT; WEIGHT GAIN; ASIAN CONTINENTAL ANCESTRY GROUP; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 77950914166     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1104     Document Type: Article

References (27)

1. Adams CE, Fenton MK, Quraishi S, David AS. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179: 290-299. (Pubitemid 32996037)
2. Bostwick JR, Guthrie SK, Ellingrod VL. 2009. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29(1): 64-70.
3. Brown CS, Markowitz JS, Moore TR, Parker NG. 1999. Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 33(2): 210-217.
4. Byerly MJ, Nakonezny PA, Lescouflair E. 2007. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 30(3): 437-452.
5. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346(1): 16-22.
6. Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L. 1994. Depot antipsychotic drugs. Place in therapy. Drugs 47(5): 741-773.
7. Eerdekens M, Rasmussen M, Vermeuzen A, Lowenthal R, Vanpeer A. 2000. Kinetics and Safety of a Novel Risperidone Depot, in 2000 Annual Meeting New Research Program and Abstracts. American Psychiatric Association: Washington, DC (number 669).
8. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70(1): 91-100. (Pubitemid 38916632)
9. Ereshefsky l, Masceranas CA. 2003. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 64: 18-23.
10. Fleischhacker WW, Eerdekens M, Karcher K, et al. 2003. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry 64: 1250-1256.
11. Gharabawi GM, Bossie CA, Zhu Y, Mao L, Lasser RA. 2005. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 77(2-3): 129-139. (Pubitemid 41112207)
12. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotics. Am J Psychiatry 160: 1125-1132. (Pubitemid 41070972)
13. Kane JM. 2007. Treatment adherence and long-term outcomes. CNS Spectr 12(10 Suppl 17): 21-26.
14. Kapur S, Remington G. 2001. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52: 503-517. (Pubitemid 32195338)
15. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. 2005. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 8(3): 427-438.
16. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. 2008. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 69(1): 47-53. (Pubitemid 351281996)
17. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005 Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. 2005.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12): 1209-1223.
18. Llorca PM. 2008. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 161: 235-247.
19. Marder SR. 1986. Depot neuroleptics: side effects and safety. J Clin Psychopharmacol 6(Suppl 1): 24S-29S.
20. Masand PS, Narasimhan M. 2006. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 1(1): 47-56.
21. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. 2009. Duration of pharmacotherapy with long-acting risperidone in the treatment of schizophrenia. Psychiatr Q 80: 241-249.
22. Möller HJ. 2007. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 67(11): 1541-1566. (Pubitemid 47267297)
23. Nayak RK, Doose DR, Nair NP. 1987. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 27(2): 144-150.
24. Parellada E, Andrezina R, Milanova V, et al. 2005. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmocol 19(5): 5-14. (Pubitemid 41392292)
25. Ramstack J, Grandolfi G, Mannaert E, D'Hoore P, Lasser RA. 2003. Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb® microsphere technology. Schizophr Res 60: 314.
26. Robinson D, Woerner MG, Alvir JM, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56(3): 241-247. (Pubitemid 29125132)
27. Ueda M, Hirokane G, morita S, et al. 2006. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 30: 486-491.